计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
OSI-930是一种新型有效的Flt1、激酶插入结构域受体(KDR)、CSF-1R、Lck、c-Raf和活化受体酪氨酸激酶Kit的抑制剂,IC50值分别为8、9、15、22、41和80 nM。
在其存活高度依赖于Kit 信号的HMC-1细胞系中,OSI-930抑制细胞增殖,诱导细胞凋亡。反之,在正常培养条件下的COLO-205细胞系中,OSI-930不抑制细胞生长。
OSI-930可时间和浓度依赖地使P450 3A4失去活性。此外,OSI-930可减少P450 3A4的CO差光谱。
OSI-930是一种有效的Kit (c-Kit), KDR和CSF-1R抑制剂,IC50分别为80 nM, 9 nM和15 nM,对Flt-1, c-Raf和Lck具有适度的抑制活性,对PDGFRα/β, Flt-3和Abl抑制活性较弱。
Information
OSI-930 is a potent inhibitor ofKit (c-Kit),KDRandCSF-1RwithIC50of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. Phase 1.
In vitro
OSI-930 inhibits the cell proliferation in the HMC-1 cell line with IC50 of 14 nM without significant effect on growth of the COLO-205 cell line that does not express a constitutively active mutant receptor tyrosine kinase. Moreover, OSI-930 also induces apoptosis in HMC-1 cell line with EC50 of 34 nM. A recent study shows that OSI-930 inactivates purified, recombinant cytochrome P450 (P450) 3A4 with a Ki of 24 μM in a time- and concentration-dependent mode.
In vivo
OSI-930, administrated at the maximally efficacious dose of 200 mg/kg by oral gavage, exhibits potent antitumor activity in a broad range of preclinical xenograft models including HMC-1, NCI-SNU-5, COLO-205 and U251 xenograft models.
Cell Data
cell lines:
Concentrations:0--1 μM
Incubation Time:48 hours
Powder Purity:≥99%
| ALogP | 6.2 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | O408316 |